U.S. Drug Administration approves long-acting antibody AstraZeneca Evusheld (AZD7442)

AstraZeneca’s Evusheld is a long-acting combination of antibodies (tixagevimab and cilgavimab) approved by the U.S. Drug Administration (FDA) for emergency use to prevent COVID-19. The first shipments are expected to be available soon.